BCI Pharma is an innovative biopharmaceutical company that specializes in the discovery of small molecule drugs, particularly focusing on the development of novel, potent, and selective kinase inhibitors. Their proprietary platform integrates advanced biological research with a diverse chemical library, enabling the identification of new chemotypes with favorable physicochemical properties. This technology aims to address significant unmet medical needs in various therapeutic areas, including chronic pain, central nervous system disorders, inflammation, and cancer. BCI Pharma's commitment to innovation is reflected in their ongoing research programs, which have already yielded a preclinical candidate for treating peripheral neuropathic pain and psoriasis.

The company's kinase inhibitor platform is distinguished by its innovative cell-based assay screening technology, which enhances the efficiency and effectiveness of drug discovery. BCI Pharma actively protects its intellectual property through a series of patent applications, ensuring that their cutting-edge research and development efforts are safeguarded. By focusing on high-performance platforms and a collaborative risk-sharing model, BCI Pharma is well-positioned to advance its pipeline of kinase inhibitors and contribute significantly to improving patient outcomes in various disease areas.

France

BCI Pharma is an innovative bio-pharmaceutical company focused on small molecule drug discovery. We design innovative chemical libraries and our HTS platform can support your owned library synthesis.

Founded by :
- Dr. Dominique Surleraux who was head of research for a pharmaceutical company (J&J) and two biotech companies (Idenix and Tibotec). 
- Dr. Elisabeth Picou who had a position in a hospital, treating patients with infectious diseases.

BCI PHARMA

Company Details